BioMarin CEO on making a difference in patients' lives

Tuesday, 17 Sep 2013 | 6:45 PM ET

BioMarin Pharmaceutical is the developer of orphan drugs for ultra-rare genetic disorders. The stock has been red hot and is up 245 percent in the last 3 years. JJ Bienaime, CEO, provides insight into the pharmaceutical company.